Drug Database
Back to search

Poland· PL-100157000

Orencia

A abatacept product containing abataceptum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.

ATC L04AA24

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOrenciaATCL04AA24REGISTER NO.PL-100157000PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about abataceptumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Abatacept is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AA24 (abatacept), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search abatacept products by name

Abatacept · ATC L04AA24

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of abatacept costs, country by country.

Normalised to the WHO defined daily dose (27 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Abatacept · price per daily dose (27 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$59.45
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Abataceptum
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Poland (PL)
ATC code
L04AA24
ATC class
Abatacept
Defined daily dose
27 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909990042296
  • gtin
    05909990042302
  • gtin
    05909990042340

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

63 interactions on record for abatacept.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check abatacept against other medicinesHow interaction checks work

Abatacept · interactions on record

63 records

  • 30 severe
  • 26 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Abatacept in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All abatacept products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Orencia
  • Liechtenstein · Orencia
  • Norway · Orencia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bc82cf27-4446-45cc-a348-1e6a26f5aa7b
GET /v1/drugs/bc82cf27-4446-45cc-a348-1e6a26f5aa7b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "250 mg",
  "packaging": "05909990042296 ¦ Rpz ¦ EU/1/07/389/001 ¦ 12421\n1 fiol.  + 1 strzyk.\n05909990042302 ¦ Rpz ¦ EU/1/07/389/002 ¦ 12707\n2 fiol.  + 2 strzyk.\n05909990042340 ¦ Rpz ¦ EU/1/07/389/003 ¦ 14150\n3 fiol.  + 3 strzyk.",
  "substance": "Abataceptum 250 mg",
  "common_name": "Abataceptum",
  "pl_product_id": "100157000",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about abatacept.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console